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Abstract
The most difficult clinical questions in stroke rehabilitation are “What is this patient’s potential for recovery?” and “What is 
the best rehabilitation strategy for this person, given her/his clinical profile?” Without answers to these questions, clinicians 
struggle to make decisions regarding the content and focus of therapy, and researchers design studies that inadvertently 
mix participants who have a high likelihood of responding with those who do not. Developing and implementing biomarkers 
that distinguish patient subgroups will help address these issues and unravel the factors important to the recovery process. 
The goal of the present paper is to provide a consensus statement regarding the current state of the evidence for stroke 
recovery biomarkers. Biomarkers of motor, somatosensory, cognitive and language domains across the recovery timeline 
post-stroke are considered; with focus on brain structure and function, and exclusion of blood markers and genetics. 
We provide evidence for biomarkers that are considered ready to be included in clinical trials, as well as others that are 
promising but not ready and so represent a developmental priority. We conclude with an example that illustrates the utility 
of biomarkers in recovery and rehabilitation research, demonstrating how the inclusion of a biomarker may enhance future 
clinical trials. In this way, we propose a way forward for when and where we can include biomarkers to advance the efficacy 
of the practice of, and research into, rehabilitation and recovery after stroke.
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Introduction
Stroke is a heterogeneous condition, making choice of treat-
ment, and prediction of outcome and treatment response, 
difficult. Despite this, clinical trials are often designed with 
a ‘one size fits all’ point of view, which can make them 
vulnerable to patient heterogeneity, reduced statistical 
power, and thus failure. Biomarkers can greatly inform 
patient selection for trials in general medical research, and 
this is equally true for stroke recovery. A stroke recovery 
biomarker (SRB) can be defined as an indicator of disease 
state that can be used as a measure of underlying molecular/
cellular processes that may be difficult to measure directly 
in humans, and could be used to understand outcome, or 
predict recovery or treatment response.1
In practical terms, biomarkers should improve our 
ability to predict long-term outcomes after stroke across 
multiple domains. This is beneficial for: (a) patients, 
caregivers and clinicians; (b) planning subsequent clini-
cal pathways and goal setting; and (c) identifying whom 
and when to target, and in some instances at which dose, 
with interventions for promoting stroke recovery.2 This 
last point is particularly important as methods for accu-
rate prediction of long-term outcome would allow clini-
cal trials of restorative and rehabilitation interventions to 
be stratified based on the potential for neurobiological 
recovery in a way that is currently not possible when tri-
als are performed in the absence of valid biomarkers. 
Unpredicable outcomes after stroke, particularly in those 
who present with the most severe impairment3 mean that 
clinical trials of rehabilitation interventions need hun-
dreds of patients to be appropriately powered. Use of 
biomarkers would allow incorporation of accurate infor-
mation about the underlying impairment, and thus the 
size of these intervention trials could be considerably 
reduced,4 with obvious benefits. These principles are no 
different in the context of stroke recovery as compared to 
general medical research.5
Interventions fall into two broad mechanistic catego-
ries: (1) behavioural interventions that take advantage of 
experience and learning-dependent plasticity (e.g. motor, 
sensory, cognitive, and speech and language therapy), and 
(2) treatments that enhance the potential for experience 
and learning-dependent plasticity to maximise the effects 
of behavioural interventions (e.g. pharmacotherapy or 
non-invasive brain stimulation).6 To identify in whom 
and when to intervene, we need biomarkers that reflect 
the underlying biological mechanisms being targeted 
therapeutically.
Our goal is to provide a consensus statement regarding 
the evidence for SRBs that are helpful in outcome predic-
tion and therefore identifying subgroups for stratification 
to be used in trials.7 We focused on SRBs that can investi-
gate the structure or function of the brain (Table 1). Four 
functional domains (motor, somatosensation, cognition, 
and language (Table 2)) were considered according to 
recovery phase post stroke (hyperacute: <24 h; acute: 1 to 
7 days; early subacute: 1 week to 3 months; late subacute: 
3 months to 6 months; chronic: > 6 months8). For each 
functional domain, we provide recommendations for bio-
markers that either are: (1) ready to guide stratification of 
subgroups of patients for clinical trials and/or to predict 
outcome, or (2) are a developmental priority (Table 3). 
Finally, we provide an example of how inclusion of a clin-
ical trial-ready biomarker might have benefitted a recent 
phase III trial. As there is generally limited evidence at 
this time for blood or genetic biomarkers, we do not dis-
cuss these, but recommend they are a developmental pri-
ority.9–12 We also recognize that many other functional 
domains exist, but focus here on the four that have the 
most developed science.
A challenge across the reviewed literature was to 
determine where the biomarker data explained recovery 
beyond that denoted by clinical outcome measures, such 
as the proportional recovery rule that has been demon-
strated using motor,3,13 visuospatial neglect14 and lan-
guage15 outcomes. Given the recency of these models, 
we were unable to address this in this paper and urge 
people to consider this in their future trial design. Further, 
to fully understand the predictive capacity of biomark-
ers, we need to move beyond cross-sectional studies, 
which constitute the bulk of the biomarker literature at 
present, and conduct mechanistic studies that go beyond 
simple correlations, as well as conduct longitudinal stud-
ies that provide data useful for predicting outcome or 
treatment response.
Motor
Neuroimaging biomarkers include quantitative characteri-
sation of the stroke lesion itself, as well as the structure and 
function of non-lesioned brain areas. There is little consen-
sus regarding the usefulness of characterizing the ischemic 
penumbra at the hyper-acute stage in relation to predicting 
motor outcomes. Recent data suggest that the site of isch-
emic penumbra, rather than volume, could predict outcome 
or treatment response (i.e. to thrombolysis) and affect motor 
recovery.16 Acute infarct volume correlates with motor out-
come (National Institute of Health Stroke Severity 
(NIHSS)), but this relationship is attenuated with increasing 
leukoaraiosis severity.17,18 The extent of existing white mat-
ter disease (i.e. leukoaraiosis) has been associated with 
acute lesion size, degree of lesion expansion and stroke 
severity indicated by initial NIHSS score.19 These findings 
underscore the point that biomarker performance varies 
across different stroke subgroups.
Measures of corticospinal tract (CST) white matter 
integrity in the acute stage may predict motor outcome. 
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Early measurement of CST fiber number via diffusion ten-
sor imaging (DTI), a reflection of white matter integrity, 
predicts motor outcome (Fugl–Meyer score) at 12 months, 
especially for patients with initially more severe impair-
ment.20 Other data,21 though not all,22 also suggest that frac-
tional anisotropy (FA) of the ipsilesional and contralesional 
CST at the acute stage is higher in individuals who achieve 
better motor recovery after stroke. Data also support the 
potential utility of the asymmetry between the ipsilesional 
and contralesional CST FA to predict treatment gains in the 
chronic stage.23
Measures of the extent of CST injury in the acute stage, 
such as via CST lesion load,24 also have predictive value for 
poor motor outcome. A model including this biomarker 
improved prediction of Fugl–Meyer motor score at three 
months post-stroke that was beyond what could be deter-
mined by baseline behavioral assessment, age or infarct 
volume. Several studies have found that in the chronic 
stage, the extent of CST injury also helps predict treatment 
gains.25–27
Other regions distant from the lesion influence motor 
recovery. While measures related to distant regions require 
further development to reach the stage of valid biomarker, 
several useful observations have been published in the 
chronic stage, including those related to contralesional 
CST,28 corpus callosum,29 precentral gyral,30 and superior 
longitudinal fasciculi.31,32 Multivariate machine learning 
methods have recently been applied to neuroimaging data 
with the aim of providing individual predictions based on 
an approach that integrates features extracted from brain 
voxels from multiple brain areas, rather than one area.33 In 
patients presenting with severe upper limb impairment, 
classification of a subsequent good or poor recovery was 
more accurate using lesion information from a range of 
cortical and subcortical motor-related regions compared to 
just using CST (87% compared to 73% accuracy respec-
tively).34 Such approaches emphasize the importance of 
taking account of damage in multiple brain regions, 
extending beyond CST, in order to better understand vari-
ation in motor outcome.34–36
There is broad consensus that the presence of an upper 
limb motor evoked potential (MEP) in response to transcra-
nial magnetic stimulation (TMS) at the hyperacute and 
acute stages strongly predicts good motor outcome37,38 and 
that shorter MEP latencies and central motor conduction 
times are associated with better outcome.39 The presence of 
a MEP has been found to identify which patients will follow 
the proportional recovery rule.40 Similarly, in the leg, the 
Table 1. Summary of Possible Brain Biomarkers to Measure Brain Structure or Function.
Measures of structure/injury: Measures of function:
•  Computed tomography (CT)
•  Diffusion tensor imaging (DTI)
•  Diffusion weighted imaging (DWI)
•  Fluid Attenuation Inversion Recovery (FLAIR)
•  Gradient echo and spin echo (GRASE)
•  T1-weighted MRI
•  T2-weighted MRI
•  Proton density-weighted MRI
•  Electroencephalograpy (EEG)
•  Functional magnetic resonance imaging (fMRI)
•  Magnetoencephalography (MEG)
•  Magnetic resonance spectroscopy (MRS)
•  Near Infrared Spectroscopy Imaging (NIRSI)
•  Positron emission tomography (PET)
•  Resting state magnetic resonance imaging (rsMRI)
•  Sensory electroencephalography (sEEG)
•  Transcranial magnetic stimulation (TMS)
Table 2. Scope of Functional Domains Considered Given Existing Literature.
Motor refers to motor outcomes, inclusive of upper and lower limb functions.
Sensation refers to somatosensation, touch and proprioception.
Cognition refers to ‘executive functioning’ or ‘cognitive control’, which are umbrella terms for sub-processes of selective attention, 
error monitoring, decision-making memory and response inhibition.
Language refers to spoken language production, auditory language comprehension, and global measures of language function (that also 
include reading and writing).
Table 3. Scope for Expert Consensus Biomarker Recommendations.
Ready to be used in clinical trial means that based on the available evidence it is recommended that the biomarker should be included in 
stroke clinical trials (pilot and feasibility work through to phase II/III/IV trials).
Development priority refers to biomarkers where there is some evidence in human populations with stroke, but questions remain or 
the evidence is insufficient to support the inclusion of this biomarker in clinical trials at present. Predictive data of outcome and/or 
recovery is needed to establish its utility in clinical trials.
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presence of a MEP indicates that an individual is more 
likely to be independently mobile 12 months post-
stroke,41–43 yet this measure does not relate to walking 
recovery.13 Prediction of recovery is more challenging for 
patients without an MEP40,44 and combining TMS with MRI 
biomarkers may be useful in this context38 TMS at the 
chronic stage helps explain the relationship between corti-
comotor function and motor performance in cross-sectional 
studies, and those who have an MEP are more likely to ben-
efit from physical interventions.23,45,46
Resting state functional connectivity (rsFC) findings in 
the early and late subacute phases converge on the conclu-
sion that interhemispheric connectivity is of particular 
importance to motor control. Cross-sectional studies have 
demonstrated decreased rsFC correlates with the degree of 
motor impairment.47,48 The are positive associations 
between acute/early subacute rsFC (ipsilesional primary 
motor cortex [M1] to contralesional thalamus, supplemen-
tary motor area (SMA), and medial frontal gyrus) and motor 
outcomes at six months (Fugl–Meyer score).49 In late sub-
acute patients, the amount of CST damage combined with 
interhemispheric M1 rsFC best predicted therapy-induced 
gains.27 Fan et al.50 found that in late subacute patients, 
change in interhemispheric M1-M1 rsFC predicts improve-
ments in the Wolf Motor Function Test. Results from a ridge 
regression machine-learning algorithm analysis of a large 
sample of early subacute stroke patients suggest that rsFC 
may explain a smaller amount of the behavioral variance 
observed than the amount of structural damage to the CST.51 
As rsFC can be performed in patients with severe deficits 
after stroke and can interrogate all brain networks simulta-
neously, it represents a priority for development.
Quantitative indices extracted from functional MRI 
(fMRI) in the early and late subacute stage, such as the lat-
erality index from M1, and the study of its change over 
time, show that stroke is associated with a less lateralized 
pattern of activation as compared to healthy subjects, a 
finding that is exaggerated among patients with poorer out-
comes.52,53 One unifying conclusion across studies is that 
the best motor outcomes are associated with the greatest 
shift towards the normal state of brain function.54 The later-
ality index has been used as a judgment criterion of efficacy 
in the chronic stage in trials testing mirror therapy,55 con-
straint-induced therapy56 and robotic intervention proto-
cols,57 and can predict treatment response.58 Other fMRI 
metrics such as activation volume59,60 or percent signal 
change61 within key motor network nodes can predict 
response to treatment in the chronic stage. As there are 
fewer long-term studies of the laterality index, and it often 
shows significant biological associations, this is an area of 
priority for development.
Magnetoencephalography (MEG) or electroencephalog-
raphy (EEG), non-invasive measures of cortical neuronal 
oscillations, are sensitive to alterations in both GABAergic 
and glutamatergic signalling that are important for plasticity 
and recovery after stroke.62–64 Changes in cortical excitation 
and inhibition represent novel therapeutic targets, but cannot 
be measured directly in humans. Stroke patients with poorer 
outcomes have persistent, increased low-frequency oscilla-
tions at the acute, and early/late subacute stages,65 suggesting 
predominant inhibitory mechanisms in the peri-lesional cor-
tex. Acutely, lower beta-rebound in response to tactile finger 
stimulation (which indicates increased early post-stroke sen-
sorimotor excitability)66and increased somatosensory map 
size67 predict good recovery after stroke. Also, in a single 
stroke patient, zolpidem reversed increased peri-lesional 
theta (4–10 Hz) and beta oscillations leading to clinical 
improvement.68 In the chronic phase, dense array EEG was 
able to predict motor gains from a four-week intensive train-
ing program.69 While MEG/EEG cannot currently be recom-
mended to guide subgroup stratification in trials at present, 
this is a developmental priority.
Combining neuroimaging and neurophysiology bio-
markers may be useful for predicting motor outcomes and 
therapy response.70 Upper limb outcomes at three months 
can be predicted at the early sub-acute stage by measuring 
first clinical, then TMS and finally MRI biomarkers in a 
stepdown approach, as in the PREP algorithm.71,72 Stoykov 
and Stinear73 treated chronic stroke patients using active-
passive bilateral arm training and discovered that fractional 
anisotropy asymmetry between the two CST tracts 
accounted for 40% variability in clinical improvement. 
Factoring in whether patients were MEP+/− improved the 
predictive model. One recent study emphasized that com-
bining neuroimaging measures of neural injury and neural 
function was key to best predicting response to a standard-
ized robotic therapy in the chronic stage.27
In summary, neuroimaging and neurophysiology CST 
biomarkers can predict motor outcome and response to 
therapy after stroke, and are recommended for use in clini-
cal trials, e.g. for stratifying patients. The evidences for 
rsFC, fMRI and MEG/EEG biomarkers are promising and 
are developmental priority areas (Table 4a).
Somatosensory
Currently, there are few studies of structural or functional 
biomarkers conducted to understand outcome, predict recov-
ery or predict treatment response in the somatosensory func-
tioning domain in the hyperacute or acute phases post-stroke. 
Most work on structural biomarkers involving the non-
lesioned brain has focused on understanding outcome by 
mapping the structural integrity of residual pathways. 
Feasibility of visualisation of sensorimotor systems by 
tracking fibres has been demonstrated in hyperacute, acute 
and early subacute phases for somatosensory symptoms.74 
There are changes in morphology of the somatosensory cor-
tex of chronic stroke patients,75 with co-localized structural 
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(cortical thickness) and functional (brain activation, tactile 
stimulation) effects. Only one study noted associations 
between the structure of somatosensory regions and motor 
outcome in the chronic phase.76
Table 4. Expert Consensus Biomarker Recommendations.
A) Motor
Ready to be used in clinical trial.
•	 CST indexed by DTI or by lesion overlap in the hyperacute, acute, early and late subacute, and chronic phases, which has 
demonstrated a moderate to strong relationship with impairment (outcome and recovery)
•	 TMS measure of MEP+ or MEP- of the upper limb to understand and track motor recovery up to the late subacute phase 
and understand the effects of rehabilitation interventions up to the chronic phase post-stroke. There is evidence of a strong 
relationship between impairment (outcome and recovery) and MEP status. We recommend that future studies of upper limb 
interventions determine whether patients are MEP+ or MEP- for the purposes of stratification.
Developmental priority
•	 Lesion location measured in the hyperacute phase. Identifying critical areas damaged that could predict recovery or treatment 
response may be important. Combining location and volume of stroke damage using multivariate techniques is the next logical step.
•	 Leukoaraiosis and covert lesions in the hyperacute, early and late acute and chronic phases require further validation to 
understand how they impact motor recovery.
•	 Accumulate further evidence of the usefulness of MEP+/- in the lower limb.
•	 Determining the utility of the laterality index from functional MRI as a predictor of efficacy in earlier stages post stroke is a 
developmental priority.
•	 Determine the utility of measures of rsFC and task-based activation and MEG/sEEG to predict treatment response in the early 
subacute, late subacute and chronic stages of recovery.
B) Somatosensory
Ready to be used in clinical trial
•	 There are no somatosensory system biomarkers ready for clinical trials.
Developmental priority
•	 Understand outcome and predict somatosensory recovery in the acute through to chronic stages using:
o	 Biologically reliable measures of white matter fibre tract integrity and connectivity within and across brain networks e.g. using 
diffusion-based tractography.
o	 Measures of rsFC, and fMRI activation.
C) Cognition
Ready to be used in clinical trial
•	 There are no biomarkers ready to be used in clinical trials.
Developmental priority
•	 Understand outcome and predict recovery in the acute to chronic stages of recovery using
o	 Measures of white matter integrity within both lesioned and non-lesioned areas.
o	 Measures of rsFC and task-based FC.
•	 Predict treatment response in the early subacute, late subacute and chronic stages of recovery using measures of rsFC and fMRI 
activation.
D) Language
Ready to be used in clinical trials
•	 Index structural damage as per PLORAS imaging protocol in the chronic phase of recovery to understand outcome and predict 
recovery. When the PLORAS database is used with an individual’s lesion information combined with time post-stroke and speech 
behaviour it provides a strong predictor of longitudinal aphasia recovery.
Developmental priority
•	 Index structural damage to and integrity of the arcuate fasciculus with diffusion weighted imaging in the late subacute and chronic 
phases of recovery to understand and predict outcome.
•	 Predict recovery using perfusion CT and MRI in the hyperacute phase.
•	 Determine if structural damage predicts therapy or treatment response in the subacute through to chronic phases.
•	 Predict recovery and treatment response in subacute to chronic phase using measures of task-based fMRI activation.
•	 Explore measures of inter and intra-network connectivity (including rsFC) and multivariate connectome-based symptom mapping 
for prediction of outcome and treatment response.
CST: corticospinal tract; CT: computed tomography; DTI: diffusion tensor imaging; FC: functional connectivity; fMRI: functional magnetic 
resonance imaging; MEP+: motor evoked potential present; MEG: magnetoencephalography; MEP-: motor evoked potential absent; MRI: magnetic 
resonance imaging; PLORAS: predicting language recovery and outcome after stroke; rsFC: resting state functional connectivity; sEEG: sensory 
electroencephalography.
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Failure to activate the somatosensory cortex during 
median nerve stimulation in the acute stage predicts poor 
clinical recovery at three months.77 Using MEG, reduction 
in interhemispheric asymmetries of activity at chronic com-
pared to acute phases was associated with a worse clinical 
state.78 Studies using MEG in early and late subacute phases 
show that changes in source strength of the primary somato-
sensory cortices correlate with the extent of recovery of 
sensorimotor functions as determined by neurological 
exams (e.g. graphesthesia test).79 Yet, MEG can be compli-
cated to employ, and so broader evaluation of these findings 
might benefit from use of less complex electrophysiological 
methods such as EEG. In the subacute phase, differences in 
brain activity measured with task-related fMRI correlated 
with touch impairment in patients with thalamus /internal 
capsule lesions compared to those with lesions of primary 
(SI) or secondary (SII) somatosensory cortex.80 Similarly, 
responsiveness of SI at 1–15 days post-stroke is associated 
with improvement of two-point discrimination three months 
post-stroke.81 Resting-state FC studies of touch impairment 
and recovery in the chronic phase demonstrated a correla-
tion between changes in connectivity from contralesional 
SII and contralesional inferior parietal and middle temporal 
gyrus with changes in a tactile discrimination score that 
were absent in a control group.82
Associations are observed between somatosensory func-
tion (using the Hand Active Sensation Test) and a left/right 
FA ratio from the sensory component of the superior tha-
lamic radiation in the chronic stage83 and the frontoparietal 
tracts in the acute84 and chronic85 phases. In addition, 
somatosensation function in the chronic phase correlates 
with activity in the ipsilesional and contralesional primary 
sensorimotor cortex86 and a more distributed pattern of 
activity involving parietal cortex.83 Improvement in touch 
discrimination at six months was associated with increased 
rsFC between seeds in the contralesional hemisphere and 
distributed regions, including cerebellum.82 Using MEG, 
involvement of ipsilesional primary hand representation 
areas positively contributed to clinical recovery.87
Changes have also been reported in association with 
training of touch discrimination,88 passive proprioception89 
and sensorimotor function,90 with a focus on tracking out-
comes and mechanisms, rather than prediction. For exam-
ple, touch discrimination training of patients with 
somatosensory loss in the chronic stage post-stroke was 
associated with different patterns of change in activation 
with thalamic/capsular compared to SI/SII cortical lesion.88 
This area of research is a priority for development.
There is insufficient evidence to recommend the use of 
any specific biomarkers of somatosensory system function 
in clinical trials; however, several candidates are suggested. 
The recovery of somatosensation is often overlooked 
despite well-documented observations that impaired sensa-
tion is an impediment to optimal recovery.91–93 Functional 
biomarkers, including task-related activation and rsFC are a 
developmental priority (Table 4b).
Cognition
Mapping executive/cognitive functions to specific brain 
regions is problematic because these functions are distrib-
uted widely across broad brain networks, and their relation-
ships are complex. Indeed, studies that readily identify 
structure–function relationships for phonology and seman-
tic processing, and often fail to find an equivalent for execu-
tive function.94 The most consistent relationships were 
found in white matter. Frontal and basal ganglia region 
microbleeds were associated with executive dysfunction 
outcome in the chronic phase,95 and another study found 
that mean diffusivity of normal appearing white matter 
(whole brain) in non-lesioned areas correlated with out-
comes for executive function among individuals with isch-
aemic leukoaraiosis (plus a previous lacunar stroke).96,97 
EEG changes in frontal lobes paralleled behavioral gains 
across multiple cognitive domains in one study that used 
intensive video gaming in health adults98; the same may 
extend to patients with stroke.
Though functional imaging methods may offer the best 
hope of generating robust biomarkers for executive func-
tion, there is little published work. Available associations 
are correlative and from cross-sectional studies, rather than 
predictions of outcomes or more complex evaluation of bio-
logical hypotheses. In the late subacute phase, executive 
functioning correlates with alpha band functional connec-
tivity between the left fronto-opercular cortex and the rest 
of the brain.99 Yet, it is possible that the task-dependent 
changes observed with functional imaging data have less to 
do with new domain-specific areas being generated, and 
more to do with cognitive control networks improving 
residual performance.100 In individuals with chronic post-
stroke aphasia, a positive correlation between task-depen-
dent activity in midline frontal cortex and language recovery 
was interpreted as reflecting domain-general cognitive con-
trol systems,101 a finding that is consistent with training 
effects in healthy elderly subjects.98 Development of bio-
markers in this context would likely foster advances in ther-
apeutic techniques to train executive function, a key priority 
that is feasible.102
The default mode network (DMN) has emerged as a key 
biological substrate in the context of cognitive functioning.103 
Studies in the subacute and early chronic phases report altered 
rsFC in the DMN correlated with cognitive performance after 
stroke104–107 Re-emergence of the anticorrelation between the 
DMN and task-positive networks, such as the dorsal attention 
network (DAN),108 is associated with behavioural recovery of 
cognitive functions. Resting state studies have provided 
robust examples of disruption of interhemispheric connectiv-
ity associated with domain-specific cognitive deficits47,51,109,110 
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and recovery.111 In a small longitudinal study of stroke patients 
compared to healthy controls, He et al.109 showed a robust cor-
relation between left-right posterior intraparietal sulcus rsFC 
and accuracy of detection of targets presented in the left 
neglected visual field. Multiple studies have confirmed this 
connectivity is much depressed in the acute stage after stroke 
in persons with USN and returns toward normal in association 
with the resolution of symptoms, with the largest current lon-
gitudinal study retaining 64 stroke patients at 12 months. 
Similar relationships have been reported for the DMN and 
other networks.47,51,109,110 While correlational analyses cannot 
establish causality and do not provide the predictive functions 
required of an effective SRB, the finding that a change in rsFC 
correlates with behaviour lends support to the idea that mea-
sures of network connectivity have the potential to serve as 
useful biomarkers across multiple behavioural domains, a 
possibility that requires further studies.
In the domain of spatial cognition, multiple moderately 
sized studies of right hemisphere injury confirm that dam-
age to different major long range white matter tracts may 
predict chronic persistence of unilateral spatial neglect. 
Two well-designed longitudinal studies implicate the infe-
rior occipitofrontal fasciculus and uncinate fasciculus112 
and decreased FA in the left and right superior longitudinal 
fasciculus II, and forceps major of the corpus callosum with 
neglect scores. In cross-sectional studies, linear regression 
shows an association of unilateral spatial neglect with dam-
age to the fronto-parietal segment of the arcuate fasciculus, 
and that 78.9% and 81.6% of patients with neglect had dam-
age to the superior longitudinal fasciculus II and superior 
longitudinal fasciculus III, respectively, compared to only 
15% and 30% in patients without neglect.113 While damage 
to superior longitudinal fasciculus III, arcuate fasciculus, 
frontal aslant, and frontal inferior longitudinal fasciculus 
are increasingly implicated in abnormal spatial cognition.114 
Whether damage to any of these white matter structures as 
measured in the acute phase of stroke can serve as a bio-
marker for persistence of USN in the chronic phase, or in 
stratifying or selecting patients for interventions is yet to be 
determined.
Based on this evidence, biomarkers of cognitive func-
tion, including executive functioning, are not ready for 
immediate broad implementation in clinical trials. Thus, 
further study and validation of biomarkers that explain cur-
rent state and future chante in cognitive functions are a sig-
nificant priority area for development. Resting state FC is a 
promising candidate biomarker (Table 4c), and study of its 
utility as a biomarker of recovery is emphasized here.
Language
There are a number of studies identifying a relationship 
between lesion site and aphasia,115 anatomical findings 
that suggest potential metrics to evaluate as biomarkers. 
In the hyperacute period, perfusion-weighted MRI 
showed that word comprehension deficits are strongly 
correlated with blood flow within Wernicke’s area.116 A 
related study demonstrated that lexical processing was 
more strongly related to the volume of hypo-perfused tis-
sue than the volume of lesion .117 Imaging illustrates that 
recovery of word comprehension from the hyperacute to 
acute phase (three days) is associated with reperfusion of 
Wernicke’s area.118 Recovery of naming in the hyper-
acute period is predicted by reperfusion of left posterior 
middle temporal/fusiform gyrus, Broca’s area, and/or 
Wernicke’s area.119–121 There are no established predic-
tors of long-term (>3 days) recovery from biomarkers 
assessed in the hyperacute period (<24 h); thus, this is a 
developmental priority.
Impaired repetition in the acute phase was associated 
with structural damage to the arcuate fasciculus and 
Broca’s area as well as tissue dysfunction (hypoperfu-
sion and frank damage) in the inferior portion of the left 
supramarginal gyrus and temporal-parietal junction.122 
Kummerer et al.,123also observed that impaired repetition 
at this phase was associated with posterior temporal-
parietal lesions and damage to the dorsal superior longi-
tudinal and arcuate fasciculus, while comprehension 
deficits were associated with ventral extreme capsule 
fibre damage. Measures of functional connectivity may 
also be useful in this phase, as a recent study of acute 
lacunar stroke patients observed that increased resting 
state FC between the left and right superior temporal gyri 
was correlated with poorer language function.124
In the early subacute phase, there are relationships 
between lesion location and aphasia symptoms that sug-
gest potential biomarkers. Kreisler et al.125correctly clas-
sified 67% to 94% of patients based on analysis of lesion 
location and symptoms. Forkel et al.,126demonstrated 
prediction of recovery at six months was improved by 
adding volume of the left long segment of the arcuate 
fasciculus to a regression model including age, sex, and 
lesion size; including volume of the right long segment 
of the arcuate fasciculus further improved recovery pre-
diction. Recent work by Geranmayeh et al.,127showed 
that propositional language production is predicted by 
interactions between brain networks (DMN, fronto- 
temporo-parietal, and cingulo-opercular networks) rather 
than by activity within a single individual network high-
lighting the distributed nature of language operations. 
Functional MRI activity in the early subacute phase 
shows promise as a predictor of long-term recovery when 
analyzed using a multivariate machine learning tech-
nique. Saur et al.,128employed this method with a mask of 
task-induced fMRI activity in bilateral frontal and tem-
poral regions in combination with behavioural language 
performance and age. This approach correctly predicted 
good versus poor language recovery in 86% of 
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individuals with stroke who had aphasia at two weeks. In 
the largest case-control study of subacute stroke patients 
with aphasia to date, Yang et al.124 found that in patients 
with lacunar stroke, interhemispheric rsFC was increased 
in the superior temporal gyrus, the inferior frontal gyrus 
and the lingual gyrus. Of note is the observation that the 
interhemispheric hyperconnectivity of the superior tem-
poral gyrus was inversely correlated with the aphasia 
quotient, indicating that greater connectivity was associ-
ated with worse aphasia.
Voxel-based analyses in the chronic phase has estab-
lished utility in multiple brain systems and specifically 
have identified structural damage associated with par-
ticular aphasic symptoms, distinguishing between 
semantic and phonological processes and recognition 
versus production.129–131 Arcuate fasciculus lesion load 
negatively influences speech production132 and classifies 
severe and non-severe outcomes with 90% accuracy for 
naming and 96% accuracy for speech fluency.133 The 
PLORAS (Predicting Language Outcome and Recovery 
After Stroke) system134 uses a Gaussian process model 
regression with a large database of stroke patients (from 
one month post, therefore covering early and late sub-
acute, and chronic phases) with structural MRI, demo-
graphic, and language performance to provide predictions 
of aphasia recovery at the individual level. Using this 
approach and covariate factors of time of stroke, volume, 
and 35 different brain regions, predictions of language 
outcome, and within subject changes in speech produc-
tion, have been identified.135 This method has high poten-
tial to provide measures that can serve as biomarkers to 
predict recovery.
Posterior middle temporal lobe damage can negatively 
affect aphasia therapy outcome in the chronic phase.122 
Meinzer et al.136observed a negative relationship between 
the proximity of the lesion to the hippocampus and 
response to a naming treatment. Bonilha et al.137showed 
that measures of neural network connectivity combined 
with initial behavioral deficit severity accounted for 78% 
of variance in response to anomia treatment. Several 
small studies identified a relationship between therapy 
success and integrity of the left arcuate fasciculus,138 right 
arcuate fasciculus139 and white matter in proximity to the 
hippocampus.136 Further, several fMRI studies have 
investigated treatment-induced aphasia recovery, pre-
dominantly in the chronic stage. Fridriksson122 identified 
a significant relationship between treatment-induced 
naming improvements and fMRI activity in the both a 
posterior cluster (including parietal lobe and precuneus) 
and an anterior cluster (including middle frontal gyrus 
and pars opercularis). Subsequent analyses140 showed that 
altered activity in perilesional areas was associated with 
increased naming accuracy, but measures of pre-treatment 
brain activity (as opposed to changes in activity) 
predicted improvement in semantic errors, suggesting 
additional factors contribute to treatment outcome. 
Resting state FC has also shown potential for understand-
ing and predicting aphasia recovery in the subacute and 
chronic phases (including treatment induced improve-
ments); however, larger studies are required to validate 
this approach.141
In summary, in the acute and early subacute stages, the 
use of structural MRI provides insights into the neural 
basis of language deficits, but there are not sufficient 
large studies demonstrating that these methods clearly 
improve prediction of recovery or treatment response. 
Functional brain assessments such as via fMRI show 
potential at the early subacute stage for significantly 
improving prediction of outcome;127 however, this 
approach needs validation. Structural MRI and DTI may 
forecast recovery at the late subacute and chronic stage, 
suggesting the possible use of these techniques to stratify 
patients for clinical trials, understand therapy mechanism 
and predict outcome. It should be noted that: (1) there is 
still considerable variability in outcome that is not 
accounted for by these methods, (2) each method uses a 
unique and complex analysis technique, (3) different 
aphasia treatments may engage unique networks (Table 
4d), and (4) detailed studies examining the combined util-
ity of anatomical and functional brain measures for pre-
dicting language recovery are warranted.
Conclusions
How might biomarker data be incorporated into future 
stroke recovery research? As a first point, the term 
“stroke” is inadequate, as it describes a very heteroge-
neous group of disorders that are unified by a vascular 
injury, but not by size, location, or impact of injury. 
Biomarkers present a way forward to subgroup or stratify 
patients in order to reduce variance and increase power, 
allowing for smaller sample sizes.7 Moreover, the final 
behavioral phenotype after stroke can arise from many 
different biological states, which could result in differen-
tial therapeutic responses; functional measures are com-
plementary to anatomical/injury measures. Thus, a patient 
exploiting all possible compensatory brain mechanisms 
might have little room to improve, while a similar patient 
who uses no compensatory mechanisms might achieve 
benefit.142 Furthermore, inclusion of appropriate bio-
markers may improve the ability to disentangle treatment 
responders from non-responders.
Clinical trials therefore need to base participant eligi-
bility on more than presence of a stroke, or behavioural 
status. Instead, patient selection should include appropri-
ate biomarkers; ideally, these will be linked with preclini-
cal methods as well as the biological mechanism of the 
therapy or treatment under investigation. For example, 
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recently, a threshold was defined whereby no patient in the 
early and late subacute stage with >63% injury to the CST 
achieved clinically important gains associated with a 
robotic therapy.27 This result highlights the ascendant role 
that neuroimaging measures need to play in clinical-deci-
sion making for post-stroke rehabilitation.143
A useful example comes from the recent phase III 
Everest trial,144 which relied on behavioural assessments 
to determine participant eligibility, and ultimately found 
that patients randomized to epidural motor cortex stimu-
lation did not reach the primary efficacy endpoint more 
often than patients in the control group. However, a post 
hoc analysis of patients randomized to epidural stimula-
tion found that the primary efficacy endpoint was reached 
more often (67%) by those with preserved motor evoked 
responses upon cortical stimulation compared to those 
lacking a response (27%).26 Thus, had confirmation of 
physiological integrity of the biological target been an 
eligibility criterion (as was the case in all preclinical 
studies that were translated to generate this trial), the 
effect size would have been substantially higher and the 
trial results quite different. We believe that this example 
is highly useful in illustrating the utility of biomarkers in 
recovery and rehabilitation research and expect that the 
inclusion of biomarkers will enhance future clinical 
trials.
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